PT-141 (Bremelanotide) is a synthetic peptide derived from Melanotan II. Unlike its parent compound, PT-141 was specifically developed and studied for its activity on melanocortin receptors involved in sexual function.
PT-141 acts on the MC3R and MC4R melanocortin receptors in the central nervous system. This mechanism is fundamentally different from PDE5 inhibitors, which work on the vascular system. PT-141 targets the brain pathways involved in sexual arousal.
The peptide has been studied in both male and female subjects in clinical trials. It received FDA approval under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women.
For research purposes, PT-141 is supplied as a lyophilized powder. It is reconstituted with bacteriostatic water and typically administered subcutaneously in preclinical protocols.
PT-141 sold by research peptide suppliers is for laboratory use only, regardless of the clinical status of the branded pharmaceutical version.
Disclaimer: This article is for educational purposes only. All peptides are sold for laboratory research use only. Not for human consumption.